Key Players
Competitive Landscape
Discharge dietitians and community prescribers pick post-hospital frailty nutrition by code, volume and flavour, and a product missing from the local formulary seldom reaches the patient. In one case, Aymes kept PIP codes unchanged through the ActaSolve and ActaGain rename so that existing prescriptions carried over.[1] Formulary continuity therefore counts as much as product claims.
Global groups compete on clinical evidence and range breadth, UK specialists on price per code and compact packs, and module makers on flexible protein top-ups. At the same time, muscle-focused nutrition overlaps with frailty care, and a 9.6% CAGR projected for the diabetic sarcopenia nutrition market means brands will keep adding HMB and leucine formulas to recovery ranges.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| October 2025: Nutricia adds savoury Fortimel PlantBased Protein flavours. | Flavour fatigue after discharge. | Savoury and warm-serve formats. | Longer adherence to supplement plans. |
| May 2026: Abbott launches Ensure Strength Pro in India. | Ageing adult buyers. | High-protein ranges for healthy ageing. | Self-pay sales after discharge. |
| August 2026: Fresenius Kabi sets out GMS code for Fresubin PRO Compact. | Reimbursed community supply. | Compact 125 ml packs. | Repeat prescriptions for low-appetite patients. |
Source: Future Market Insights, Post-Hospital Frailty Nutrition Market Report, 2026-2036.
Hospital tenders for discharge packs now ask for compact, savoury and powder options from one supplier, so groups with the widest ranges will gain those contracts.
Who leads the post-hospital frailty nutrition market?
Scale and prescription reach define leadership. Abbott reports the largest adult nutrition sales in the group, at USD 1,119 million for the June 2026 quarter.[6] Scale of that size funds clinical studies and wide flavour ranges. On a smaller scale, Aymes leads the UK prescription specialists.[1] Code-level pricing keeps Aymes on UK formularies against larger rivals.
Which companies have documented positions?
Listed codes and clinical data mark the strongest positions. Aymes holds listed PIP codes for each renamed line.[1] Listed codes keep repeat prescriptions in place. Likewise, Nutricia reports adherence data for Fortimel PlantBased Protein.[5] Retention figures of that kind support a switch away from sweet milk shakes at review. Finally, Fresenius Kabi holds the GMS code for Fresubin PRO Compact in Ireland.[3] A public reimbursement code gives the compact drink access to community prescribers.
What should buyers evaluate before approving a supplier?
Buyers check protein and energy per serving, volume, flavour range, reimbursement code and stock reliability, then test tolerance with a short trial pack. Dietitians also look for powder and pudding options so one supplier covers each patient as needs change.
How is competition expected to change through 2036?
Sweet 200 ml bottles will cede ground to compact packs and savoury flavours at community review. In turn, suppliers will compete harder for 90-day and 6-month plans as review pathways mature.
Representative Company Overview
| Company | Positioning | Recent development |
|---|---|---|
| Aymes | UK prescription ONS maker with powder and ready-to-use ranges | 2025 to 2026: ActaSolve and ActaGain rename with PIP codes kept. |
| Danone Nutricia | Global medical nutrition group with Fortimel and Fortisip ranges | October 2025: savoury Fortimel PlantBased Protein flavours launched. |
| Abbott | Adult nutrition group with Ensure ranges | July 2026: Q2 adult nutrition sales of USD 1,119 million. |
Research Methodology
The companies included in the report represent current market structure and do not indicate a market-share ranking. Company results, payer guidance, government statistics and trade publications support the analysis, and figures are cross-checked across company, industry and government sources.
